503A compounding
Section 503A of the Federal Food, Drug, and Cosmetic Act governs compounding by state-licensed pharmacies and physicians, generally on the basis of patient-specific prescriptions.
- Editorial attention
- Emerging
- Tracked this week
- 0
- Sources this week
- 0
- Last activity
- May 25, 2026
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
503A compounding at a glance
- About this topic
- Section 503A of the Federal Food, Drug, and Cosmetic Act governs compounding by state-licensed pharmacies and physicians, generally on the basis of patient-specific prescriptions.
- Current status
- No editor-reviewed status summary yet. The official records below update automatically.
- Last updated
- Primary sources
- Latest official record: Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (opens the source in a new tab) (Federal Register, May 25, 2026)
What’s the latest on 503A compounding?
0 totalNo briefings on this topic yet. Official records and trials below are updated continuously.
What do the official records show?
Primary sources and peer-reviewed research- Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (opens the source in a new tab)
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Reg…